Research Articles on Healthcare Inequalities in Canada
CANAAF stand with the Black community in the fight against anti-Black racism! #BlackLivesMatter! Minority populations, especially Black and Indigenous communities, are likely to experience poorer healthcare and health outcomes in Canada. These disparities in healthcare can lead to differences in the risk of developing many conditions, including Alopecia Areata. Below are a few articles
Remission of Alopecia Universalis in a Patient with Atopic Dermatitis Treated with Dupilumab
Atopic Dermatitis (AD), a type of eczema, is an inflammatory skin disorder that causes redness, itching and dryness. It has been associated with autoimmune diseases like Alopecia Areata (AA) - meaning that those with Atopic Dermatitis have a higher risk of developing AA and vice versa. In this article, it was reported that a
Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata
We are so excited to announce that yesterday the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for CoNCERT Pharmaceuticals' CTP-543, an oral Janus Kinase (JAK) Inhibitor undergoing a clinical trial for moderate to severe Alopecia Areata. Currently, there are no drugs approved in the US or Canada for the treatment of
Understanding the Risks of JAK Inhibitors
For several years now Janus Kinase (JAK) inhibitors have been the latest breakthrough in Alopecia Areata treatment. Rather than suppressing the entire immune system like conventional immunosuppressants, JAK inhibitors like Tofacitinib (Xeljanz/Xeljanz XR) and Ruxolitinib (Jakavi) suppress a specific biochemical pathway called the Janus Kinase pathway, which is involved in the autoimmune response seen
Epigallocatechin-3 Gallate as a Potential Alternative to JAK Inhibitors?
Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients For several years, the big breakthrough in Alopecia Areata research has been the discovery of using Janus Kinase (JAK) inhibitors as a treatment. While they are still the next best thing, research has shown that another molecule called Epigallocatechin-3 Gallate (EGCG) has the
Concert Pharmaceuticals Releases Additional Data From Phase 2 Clinical Trial of CTP-543 In Alopecia Areata
In phase 2 of their clinical trial testing the drug CTP-543 (a JAK 1 and JAK 2 inhibitor) as a treatment for Alopecia Areata, CoNCERT Pharmaceuticals has found that a statistically significant number of subjects have responded to the 8 mg and 12 mg oral dose of the drug given twice daily. A subject
Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.